Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined JAK/ERK Inhibition in Patients With Myelofibrosis
NCT06773195Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ulixertinib in myelofibrosis (MF), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Dose Limiting Toxicity at 28 days and Response to therapy at 25 weeks. Started Jan 2025; status: recruiting.
02
Drugs
ulixertinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06773195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773195.